A dose planning system, which takes the drug concentration distribution in human organs/tissues as well as the atomic composition distribution of human organs/tissues into consideration, and calculates the neutron/photon dose distribution in human organs/tissues under this drug concentration distribution using the Monte Carlo Method. Thereby the neutron/photon dose distribution in the organs/tissues of the human subject is calculated more accurately.

A system and method for patient positioning during radiotherapy. The system can include a patient support structure configured to receive a patient during a radiotherapy process using a radiotherapy source to deliver a therapy to the patient when positioned on the patient support structure, a patient positioning system configured to adjust a position of the patient support structure relative to the radiotherapy source, a flexible actuator configured to secure the patient to the patient support and adjust a position of the patient relative to the patient support, and an imaging system configured to acquire imaging data of the patient, the patient support, and the flexible actuator during the radiotherapy process.

A housing system for a radiotherapy apparatus (100, 200). The system comprises a support structure configured to support a source of radiation, a cover (208), and a lock (214). The cover (208) is hingeably attached to the support structure and movable between a closed position, in which the cover (208) shields the source of radiation, an open position. The lock (214) is configured to releasably lock the cover (208) in the closed position.

An embodiment provides a method for treating a body fluid of a patient with Alzheimer's Disease, including: removing the body fluid from a patient; applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with an Alzheimer's targeted antigen (TA) in the body fluid to form an antibody-TA complex, wherein the antibody comprises a radiofrequency absorption enhancer; removing the antibody-TA complex from the body fluid using a radiofrequency source; and returning the body fluid to the patient. Other aspects are described and claimed.

New compositions of tissue-equivalent three-dimensional polymer gel dosimeters based on acrylamide (AAm), N-isopropylacrylamide (NIPAM), N-(Hydroxymethyl)acrylamide (NHMA), diacetone acrylamide (DAAM) and N-Vinylcaprolactam (NVCL) monomer with ethylene glycol co-solvent have been introduced in this invention for radiotherapy dosimetry. The dosimeter was irradiated with 6 and 15 MV linear accelerator at absorbed doses up to 10 Gy. The nuclear magnetic resonance (NMR) spin-spin relaxation rate (R.sub.2) for water proton surrounding polymer formation was used to investigate the degree of polymerization of the five gels. The effect of additives, dose rate, radiation energy, stability of the polymerization after irradiation, were investigated on the dose response of the gels.

A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose distribution. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug and induce a persistent therapeutic response, the dose comprising a pulsed sequence of x-rays delivering from 0.5-2 Gy to the tumor.

A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose distribution. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug and induce a persistent therapeutic response, the dose comprising a pulsed sequence of x-rays delivering from 0.5-2 Gy to the tumor.

Disclosed herein are radiotherapy methods and systems that can display a workflow-oriented graphical user interface(s). A method comprises presenting a plurality of pages for display, each corresponding to a stage of a radiotherapy treatment for a patient; in response to receiving an indication that a surface of a patient is aligned, retrieving, from a radiotherapy file, a first image of an internal target aligned in accordance with treatment attributes; receiving a second image of the internal target; overlaying on a first page of the plurality of pages, the first image and the second image, the first page displaying a direction to position the internal target in the second image to align with the internal target in the first image; and when the internal target is aligned, presenting for display a second page of the plurality of pages corresponding to a subsequent stage of the radiotherapy treatment for the patient.

The invention is directed to biomarkers for predicting a patient's response, both therapeutic and toxic, to immunotherapy.

There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcomain a patient in need thereof.